A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer

Status:
Completed

Trial end date:
2016-09-01

Target enrollment:

Participant gender:

To evaluate the safety and efficacy of SGX942 in patients receiving chemoradiation treatment for the treatment of head and neck cancer.

Phase 2

Soligenix